These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36227102)

  • 1. Autoimmune activation and hypersensitization of the AT1 and ETA receptors contributes to vascular injury in scleroderma renal crisis.
    Hegner B; Kretzschmar T; Zhu N; Kleinau G; Zhao H; Kamhieh-Milz J; Hilger J; Schindler R; Scheerer P; Riemekasten G; Philippe A; Catar R
    Rheumatology (Oxford); 2023 Jun; 62(6):2284-2293. PubMed ID: 36227102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis.
    Becker MO; Kill A; Kutsche M; Guenther J; Rose A; Tabeling C; Witzenrath M; Kühl AA; Heidecke H; Ghofrani HA; Tiede H; Schermuly RT; Nickel N; Hoeper MM; Lukitsch I; Gollasch M; Kuebler WM; Bock S; Burmester GR; Dragun D; Riemekasten G
    Am J Respir Crit Care Med; 2014 Oct; 190(7):808-17. PubMed ID: 25181620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients.
    Günther J; Kill A; Becker MO; Heidecke H; Rademacher J; Siegert E; Radić M; Burmester GR; Dragun D; Riemekasten G
    Arthritis Res Ther; 2014 Mar; 16(2):R65. PubMed ID: 24612997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis.
    Kill A; Tabeling C; Undeutsch R; Kühl AA; Günther J; Radic M; Becker MO; Heidecke H; Worm M; Witzenrath M; Burmester GR; Dragun D; Riemekasten G
    Arthritis Res Ther; 2014 Jan; 16(1):R29. PubMed ID: 24472528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies Targeting AT
    Catar R; Herse-Naether M; Zhu N; Wagner P; Wischnewski O; Kusch A; Kamhieh-Milz J; Eisenreich A; Rauch U; Hegner B; Heidecke H; Kill A; Riemekasten G; Kleinau G; Scheerer P; Dragun D; Philippe A
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive receptor blockade and plasma exchange to treat refractory scleroderma renal crisis in patients with agonistic autoantibodies targeting the angiotensin II type 1 and endothelin-1 type A receptors.
    Hegner B; Callaghan J; Schindler R; Heidecke H; Riemekasten G; Philippe A; Catar R
    J Scleroderma Relat Disord; 2024 Feb; 9(1):NP1-NP6. PubMed ID: 38333524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Antibodies Directed Against Two GPCRs, Anti-AT1R and Anti-ETAR, on Kidney Transplant Outcome.
    El Band JEK; Llorente S; Martinez-Garcia P; Alfaro R; Jimenez-Coll V; Boix F; Galián JA; Martinez-Banaclocha H; Botella C; Moya-Quiles MR; Minguela A; Legaz I; Muro M
    Curr Protein Pept Sci; 2021; 22(10):745-757. PubMed ID: 34967284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-HLA Autoantibodies at 1 Year Negatively Affect 5-Year Native Renal Function in Liver Transplant Recipients.
    O'Leary JG; Philippe A; Freeman R; Heidecke H; Jennings LW; Catar R; Klintmalm GB; Dragun D
    Transplant Proc; 2021 Apr; 53(3):1019-1024. PubMed ID: 33579550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionally Active Antibodies to the Angiotensin II Type 1-Receptor Measured by a Luminometric Bioassay Do Not Correlate With Clinical Manifestations in Systemic Sclerosis: A Comparison With Antibodies to Vascular Receptors and Topoisomerase I Detected by ELISA.
    Bankamp L; Preuß B; Pecher AC; Beucke N; Henes J; Klein R
    Front Immunol; 2021; 12():786039. PubMed ID: 34956217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies against Angiotensin II Type 1 and Endothelin 1 Type A Receptors in Cardiovascular Pathologies.
    Civieri G; Iop L; Tona F
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II enhances endothelin-1-induced vasoconstriction through upregulating endothelin type A receptor.
    Lin YJ; Kwok CF; Juan CC; Hsu YP; Shih KC; Chen CC; Ho LT
    Biochem Biophys Res Commun; 2014 Aug; 451(2):263-9. PubMed ID: 25088996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Zmonarski S; Mazanowska O; Krajewska M; Bartoszek D; Zabińska M; Myszka M; Kamińska M; Hałoń A; Dawiskiba T; Szyber P; Sas A; Klinger M
    Transplant Proc; 2014 Oct; 46(8):2618-21. PubMed ID: 25380879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies.
    Lukitsch I; Kehr J; Chaykovska L; Wallukat G; Nieminen-Kelhä M; Batuman V; Dragun D; Gollasch M
    Transplantation; 2012 Jul; 94(1):8-13. PubMed ID: 22691955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-ETAR and anti-AT1R autoantibodies are elevated in patients with endstage cystic fibrosis.
    Budding K; van de Graaf EA; Hoefnagel T; Kwakkel-van Erp JM; van Kessel DA; Dragun D; Hack CE; Otten HG
    J Cyst Fibros; 2015 Jan; 14(1):42-5. PubMed ID: 25096855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels of angiotensin II type-1 receptor antibodies and endothelin-1 type-A receptor antibodies correlate with antibody-mediated rejection and poor graft function in kidney-transplantation patients.
    Liu C; Kang ZY; Yin Z; Xiao Y; Liu W; Zhao Y; Li DH
    Transpl Immunol; 2022 Oct; 74():101674. PubMed ID: 35901953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin and Endothelin Receptor Structures With Implications for Signaling Regulation and Pharmacological Targeting.
    Speck D; Kleinau G; Szczepek M; Kwiatkowski D; Catar R; Philippe A; Scheerer P
    Front Endocrinol (Lausanne); 2022; 13():880002. PubMed ID: 35518926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-HLA antibodies targeting angiotensin II Type 1 receptor and endothelin-1 Type A receptors induce endothelial injury via β2-arrestin link to mTOR pathway.
    Catar RA; Wischnewski O; Chen L; Heidecke H; Rutz C; Schülein R; Dragun D; Philippe A; Kusch A
    Kidney Int; 2022 Mar; 101(3):498-509. PubMed ID: 34757123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis.
    Cabral-Marques O; Riemekasten G
    Autoimmun Rev; 2016 Jul; 15(7):690-4. PubMed ID: 26970493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against angiotensin II receptor type 1 and endothelin A receptor are increased in COVID-19 patients.
    Miedema JR; Janssen ML; von der Thüsen J; Endeman H; Langerak AW; Hellemons ME; van Nood E; Peeters BWA; Baart SJ; Schreurs MWJ
    Front Immunol; 2023; 14():1204433. PubMed ID: 37622126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibodies Targeting G-Protein-Coupled Receptors: Pathogenetic, Clinical and Therapeutic Implications in Systemic Sclerosis.
    Binda M; Moccaldi B; Civieri G; Cuberli A; Doria A; Tona F; Zanatta E
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.